Universal HLA-E - restricted HIV TCR platform
This technology comprises a portfolio of HLA-E–restricted T cell receptors targeting HIV-1 peptides (including Rev and Gag epitopes), alongside encoding nucleic acids, vectors, and engineered cells.It enables universal immunotherapies capable of recognising and eliminating HIV-infected cells independent of HLA polymorphism.
Applications: HIV therapies, universal HIV immunotherapy, soluble and bispecific TCR therapeutics
| Features | Benefits |
|---|---|
| Universal targeting across all patients | By leveraging HLA-E - effectively non-polymorphic across humans - these TCRs overcome a fundamental limitation of conventional HLA-A/B/C-restricted therapies, enabling broad patient applicability without matching |
| Novel HIV epitope targeting via HLA-E | The invention identifies HIV-1 peptides (e.g. Rev IL9 and Gag KF11 variants) capable of binding HLA-E and being recognised by TCRs - expanding the known antigen landscape for HIV immunotherapy |
| Functionally validated viral suppression | TCR-engineered T cells derived from these sequences demonstrate the ability to suppress HIV replication in vitro, supporting strong translational potential for therapeutic development |
| Broad IP coverage across modalities | Claims encompass TCR sequences, variants (≥90% identity), nucleic acids, vectors (including viral delivery systems), engineered immune cells, and pharmaceutical compositions - supporting multiple product formats and licensing strategies |
| Designed for cell therapy and biologic format | The platform supports both adoptive T cell therapies (e.g. TCR-T) and soluble or bispecific TCR constructs, enabling flexibility across high-value therapeutic modalities |
Available For
- Co-development
- Consulting
- Licensing